People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

30 Oct 2020
Change (% chg)

$6.59 (+2.68%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Vounatsos, Michel 

Mr. Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences and as a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Basic Compensation

Total Annual Compensation, USD 5,272,460
Restricted Stock Award, USD 12,352,000
Long-Term Incentive Plans, USD --
All Other, USD 535,367
Fiscal Year Total, USD 18,159,900

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --